pharmaphorum

AZ and Daiichi's TROP2 ADC shows promise in first-line lung cancer

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...